Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Receivables (2020 - 2022)

Tango Therapeutics (TNGX) has 3 years of Receivables data on record, last reported at $2.0 million in Q4 2022.

  • For Q4 2022, Receivables changed 0.0% year-over-year to $2.0 million; the TTM value through Dec 2022 reached $2.0 million, changed 0.0%, while the annual FY2022 figure was $2.0 million, 0.0% changed from the prior year.
  • Receivables reached $2.0 million in Q4 2022 per TNGX's latest filing, roughly flat from $2.0 million in the prior quarter.
  • Across five years, Receivables topped out at $8.0 million in Q3 2021 and bottomed at $2.0 million in Q4 2020.
  • Average Receivables over 3 years is $2.9 million, with a median of $2.0 million recorded in 2020.
  • Peak YoY movement for Receivables: changed 0.0% in 2021, then plummeted 75.0% in 2022.
  • A 3-year view of Receivables shows it stood at $2.0 million in 2020, then changed by 0.0% to $2.0 million in 2021, then changed by 0.0% to $2.0 million in 2022.
  • Per Business Quant database, its latest 3 readings for Receivables were $2.0 million in Q4 2022, $2.0 million in Q3 2022, and $2.0 million in Q2 2022.